TargImmune raises nearly 18 million Swiss francs
The Basel-based biotechnology firm TargImmune has raised 17.7 million Swiss francs as part of a financing round. It now intends to transfer its lead candidate to clinical development. The company develops immunotherapies for the targeted destruction of tumors.
TargImmune Therapeutics develops targeted immunotherapies that fight the tumor itself, alert the immune system and destroy neighboring tumor cells. The Basel-based company now intends to transfer its lead product candidate Tar001 to clinical development and can call upon proceeds raised from a financing round for this purpose, further details of which can be found in an article published by startupticker.ch. TargImmune raised a total of 17.7 million Swiss francs in the aforementioned financing round.
Based at the Technologiepark Basel, TargImmune is developing its drug using the company’s proprietary RNA platform. Clinical development is expected to begin in the second quarter of 2022. TargImmune also plans to file an application with the U.S. Food and Drug Administration with the aim of securing Investigational New Drug status.
However, CEO Esteban Pombo-Villar is set to leave his post and will in future work as Head of Technology for the Basel-based company, which was founded back in 2016. On August 16, 2021, Peter Braun will then take over management responsibility. He has 25 years of professional experience. Most recently, he worked for the Norwegian company Nordic Nanovector.
Share this article
You may also be interested in
Evolva launches new line for manufacturers of personal care products
Evolva, a manufacturer of active ingredients based in Reinach in the canton of Basel-Landschaft, will be presenting its new product...Read More
Record figure for startups in the Basel Area
Basel Area Business & Innovation has supported a record number of 96 company startups in 2022. The number of settlements...Read More
Noema Pharma raises 103 million Swiss francs from investors
Noema Pharma has raised a total of 103 million Swiss francs as part of an oversubscribed Series B financing round....Read More
Why CDMO companies choose the Basel Area as their location
Originally, this article was published by the US magazine Outsourced Pharma under the title "Why Location Matters". The article highlights...Read More
Basel still the most attractive small city for business in Europe
As with last year, Basel once again features among the most attractive locations in Europe for investments. It was ranked...Read More
Ariceum Therapeutics establishes subsidiary in Basel
The German life sciences firm Ariceum Therapeutics has established a subsidiary in Basel. This company has received support from Basel...Read More